Infectious disease Archives

redhill biopharma nih ebola animal rule fda

News and Trends 20 Jul 2016

Israeli Biopharma joins NIH to develop Ebola Treatment

RedHill Biopharma has announced a research collaboration with the NIH. The focus will be RedHill’s new experimental treatment for Ebola, after encouraging results in preliminary studies. The Ebola outbreak of 2014 in West Africa highlighted the need for a therapy against this infectious disease, which has mortality rate ranging from 25% to 90%. The crisis spurred a […]

July 20, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 14 Jul 2016

Institut Pasteur & Austrian Biotech also join the World Zika Vaccine Plan

Themis is a Vienna-based vaccine developer. Together with the Institut Pasteur, it is now planning to use a measles vaccine construct to develop and start Zika vaccine trials within the next 12 months. Themis has successfully extended its existing license agreement with Institut Pasteur in Paris, which grants the company a broad access to a well-established virus vaccine vector technology. The […]

July 14, 2016 - 3 minutesmins - By Dani Bancroft

oxitec brazil mosquito gmo vector control zika dengue malaria city

News and Trends 14 Jul 2016

UPDATE: Brazilian city to be first in World to deploy GM Mosquitos against Dengue Fever

Oxitec‘s genetically engineered Mosquito trial is being expanded in Brazil’s Piracicaba region, to cover a city of over 60,000 people. With support from Ministry officials and the WHO, this UK biotech is making serious progress with their transgenic organism solution for Infectious diseases. UPDATE: (Article originally published 3/06/16). Just announced (14/07/16): The results from the trial […]

July 14, 2016 - 4 minutesmins - By Dani Bancroft

HIV diagnostic helen lee epo biotech inventor europe samba

News and Trends 12 Jul 2016

How did Helen Lee overcome barriers to HIV Diagnostics in the ‘Real World’?

How can diagnostics be improved in resource limited settings? And how can the practical limitations of transporting heat-sensitive assay material through hot climates be overcome? The University of Cambridge’s Dr Helen Lee won this year’s ‘Popular Choice’ Award, at the European Patent Office (EPO) awards. The winner of this prize category is selected from 15 other […]

July 12, 2016 - 6 minutesmins - By Dani Bancroft

News and Trends 11 Jul 2016

On the way to a ‘Functional’ HIV Cure? Norway Vaccine clears viral load in 88% of Patients

Oslo based Biopharma Bionor has a Phase I results for a HIV vaccine. The vaccine infusion rendered viral presence in 88% of patients undetectable after combination treatments with Celgene‘s enzyme inhibitor, Istodax and standard retroviral drugs. The positive results from the clinical trial REDUC Part B were published in the high impact journal The Lancet HIV. The Norwegian’s proprietary […]

July 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Jul 2016

Copenhagen-based Pcovery is looking to fight invasive Fungal Infections

After another visit to the United Kingdom, we ‘Brexit’ towards other geographies! We’re crossing the English Channel back to the continent and go further up to Denmark. This week, in Copenhagen, we’re visiting Pcovery, our Biotech of the Week. City: Copenhagen (Denmark) Founded: 2009 Employees: 6 Financial Data: €7.5M Total Raised (as of 12/2015) CEO: Casper Tind Hansen […]

July 8, 2016 - 2 minutesmins - By Joachim Eeckhout

zika sanofi niaid army us vaccine biotech

News and Trends 7 Jul 2016

Sanofi and the US Army team up for a Zika Vaccine, but why isn’t everyone else?

Together with the US Walter Reed Army Institute of Research (WRAIR), the French infectious disease specialist, Sanofi Pasteur, hopes to speed up their promising new Zika virus vaccine. With the concerns over the borderline epidemic of the Zika virus, with its mysterious origins and not fully understood pathophysiology, the Biotech and pharmaceutical industries have united globally […]

July 7, 2016 - 4 minutesmins - By Dani Bancroft

abivax ceo ehrlich interview hiv hepatitis

News and Trends 4 Jul 2016

“We have one of the World’s Most Advanced Functional HIV Cures under development”

Abivax has recently announced that it’s likely that its most advanced program in hepatitis B will fail its Phase III trials. That’s really bad news for the company, and stocks have plummeted by around 50%. But what does this really mean for the future of Abivax? To find out, I had a chat with the company’s CEO Hartmut […]

July 4, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 27 Jun 2016

“France has always been a Leader in Infectious Disease and Microbiology”

This is what Franck Lescure, a partner at VC firm Auriga Partners, told me when I met him in Paris at his office next to the Champs-Elysées. Their last fund, Auriga IV Bioseeds, focuses on infectious disease and microbiology, with 6 investments so far and 9 by the end of 2016. It was a great way to […]

June 27, 2016 - 4 minutesmins - By Philip Hemme

venomab recombinant antivenom laustsen refresh

News and Trends 23 Jun 2016

‘Snake-bite Jesus’ pitched at Labiotech Refresh

VenomAb made quite an impression at the Startup Battle of Labiotech Refresh. Want to know what makes a biotech audience gasp unanimously? Then take a look at VenomAb’s pitch… We had Andreas Laustsen, founder of VenomAb, pitch his startup’s mission to bring antivenoms out of the 1900s into the modern age of biotech. The idea really captured […]

June 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

f2g fungal infections antifungals aspergillosis

News and Trends 22 Jun 2016

Massive Round: Novel Antifungals get €53M from Top-Notch Investors

F2G has raised €53M to advance its news class of treatments for life-threatening fungal infections, including invasive aspergillosis. The technology has attracted some of the major biotech investors in Europe. Based in Manchester (UK), F2G focuses on developing therapies for invasive fungal infections such as aspergillosis. This type of infections mostly affect patients that are […]

June 22, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 20 Jun 2016

GMO Tobacco could Produce cheaper Medicine for Malaria

Researchers from the Max Planck Institute of Molecular Plant Physiology in Potsdam have altered tobacco to produce large yields of artemisinin – the most effective treatment for malaria but still without a cheap and reliable source. Artemisinin is used in the most effective treatments against malaria, the discovery of which was worth a Nobel Prize. […]

June 20, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us